Does surfactant type cause a differential proinflammatory response in preterm infants with respiratory distress syndrome?

[1] Ainsworth S.B.(2000)Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks’ gestation: a randomised trial Lancet 35 1387-1392

[2] Beresford M.W.(1996)A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome J Pediatr 128 396-406

[3] Milligan D.W.(1997)A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome Pediatrics 100 39-50

[4] Hudak M.L.(2000)Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant Acta Paediatr 89 510-512

[5] Farrell E.E.(1995)Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome Arch Dis Child 72 F8-F13

[6] Rosenberg A.A.(2004)A randomised, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants Am J Perinatol 21 109-119

[7] Hudak M.L.(1999)Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia Pediatr Pulmonol 24 331-336

[8] Martin D.J.(1997)Early increase of TNF alpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants Arch Dis Child Fetal Neonatal Ed 77 F198-F201

[9] Egan E.A.(2005)Interleukin-1 balance in the lungs of preterm infants who develop bronchopulmonary dysplasia Biol Neonate 87 82-90

[10] Kukkonen A.K.(1991)Phagocytic functions and tumor necrosis factor secretion of human monocytes exposed to natural porcine surfactant (Curosurf) Pediatr Res 30 69-74

[1] Ainsworth S.B.(2000)Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks’ gestation: a randomised trial Lancet 35 1387-1392

[2] Beresford M.W.(1996)A multicenter randomized, masked comparison trial of natural versus synthetic surfactant for the treatment of respiratory distress syndrome J Pediatr 128 396-406

[3] Milligan D.W.(1997)A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome Pediatrics 100 39-50

[4] Hudak M.L.(2000)Randomized trial comparing natural and synthetic surfactant: increased infection rate after natural surfactant Acta Paediatr 89 510-512

[5] Farrell E.E.(1995)Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome Arch Dis Child 72 F8-F13

[6] Rosenberg A.A.(2004)A randomised, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants Am J Perinatol 21 109-119

[7] Hudak M.L.(1999)Elevation of interleukin-8 and interleukin-6 precedes the influx of neutrophils in tracheal aspirates from preterm infants who develop bronchopulmonary dysplasia Pediatr Pulmonol 24 331-336

[8] Martin D.J.(1997)Early increase of TNF alpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants Arch Dis Child Fetal Neonatal Ed 77 F198-F201

[9] Egan E.A.(2005)Interleukin-1 balance in the lungs of preterm infants who develop bronchopulmonary dysplasia Biol Neonate 87 82-90

[10] Kukkonen A.K.(1991)Phagocytic functions and tumor necrosis factor secretion of human monocytes exposed to natural porcine surfactant (Curosurf) Pediatr Res 30 69-74